Phytotherapy in the Management of Diabetes and Hypertension: Volume 4 E-Book
48,74 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Fachliteratur
- Serie: Phytotherapy in the Management of Diabetes and Hypertension
- Sprache: Englisch
Medicinal plants are a source of potential therapeutic compounds. Phytotherapycan give patients long term benefits with less or no side effects. Phytotherapy in the Management of Diabetes and Hypertension is a book series which emphasizes the biochemistry behind diabetes mellitus and hypertension, along with the control or remediation of these conditions through cost effective, safe and easily-adaptable methods validated by scientific research.This is the fourthvolume of the series which features reviews on selected natural productsused to treat diabetes and hypertension. This volume brings 6 chapterscontributed by 14 researchers that cover general updates on diabetic phytotherapy, circumin, and the medicinal use of olive leaves, passion fruit and spiral gingers in the treatment of diabetes and hypertension.Each review covers different plant species or medicinal agents whereapplicable, providing readers essential information about their role in thetreatment of diabetes and hypertension.Both academic and professional pharmacologists as well as clinicianswill find comprehensive information on a variety of therapeutic agents in thisvolume.
Sie lesen das E-Book in den Legimi-Apps auf:
Seitenzahl: 306
Veröffentlichungsjahr: 2020
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the book/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Pte. Ltd. 80 Robinson Road #02-00 Singapore 068898 Singapore Email: [email protected]
PREFACE
In order to provide an up-to-date overview of the phytotherapy of diabetes and hypertension, this fourth volume has been prepared as part of the ebook series “Phytotherapy in the Management of Diabetes and Hypertension”. The present volume includes different aspects of the pathophysiology of diabetes and hypertension. This book adds important information related to the evaluation of the efficacy and safety of medicinal plants and their derivatives on diabetes and hypertension. The present volume includes 6 complementary chapters presenting an updates on clinical study reports of phytotherapy in the management of type 2 diabetes mellitus; curcumin: a drug of choice for the treatment of diabetes and hypertension; olive leaf, a traditional phytomedicine for diabetes and hypertension; medicinal plants from genus Costus in management of diabetes; antidiabetic and antihypertensive potential of passiflora SPP (passion fruit) - an updated review and monograph on Anvillea radiata Cross. & Durieu. This volume will be useful to the students, teachers, researchers, scientists, clinicians and even the common people.
ACKNOWLEDGMENTS AND GRANTS
The Editor would like to thank all the authors and the reviewers for their contribution to this volume. This work was supported by the Ministry of National Education, Vocational Training, Higher Education and the Scientific Research (Morocco) and the National Center for Scientific and Technical Research (CNRST) (Morocco) under grant N° PPR/2015/35.
List of Contributors
Updates on Clinical Study Reports of Phytotherapy in the Management of Type 2 Diabetes Mellitus
Md. Moklesur Rahman Sarker1,2,*,Mahfuza Afroz Soma1Abstract
Type 2 diabetes mellitus (T2DM) is a metabolic disorder caused by the insufficient production of insulin and/or the development of resistance to insulin. The long-term management of T2DM with conventional oral hypoglycaemic drugs is a challenge as these drugs may worsen certain underlying comorbidities and complications, such as chronic kidney and cardiovascular diseases. Besides, because of the development of resistance to those drugs, it is difficult to control hyperglycemia for long term treatment of type 2 diabetes mellitus patients. This drawback of conventional medicines necessitates phytotherapy, herbal medicines, functional foods, nutraceuticals, and other forms of alternative medicines or the invention of new medicines for the effective and long term treatment of type 2 diabetes mellitus avoiding the major adverse-effects or minimising them. Plant-derived bioactive compounds are a great resource for the discovery of new medicines. Besides, phytomedicines in the forms of extracts, isolated compounds, combined herbal preparations or other forms can be used for the prevention and treatment of type 2 diabetes mellitus. This chapter contains updated panorama based on the evidences from clinical study reports on different forms of phytotherapy, including plant extracts, its fractions, isolated bioactive compounds, functional foods, nutraceuticals, herbal medicines formulations and other forms of plant-derived phytotherapy reported for the treatment of type 2 diabetes mellitus. The findings from clinical study reports were discussed with proper citations as well as presented in summarized form in a table. A total of 52 different types and forms of prospective phytomedicines, bioactive compounds, or formulation or extracts or fractions or decoctions or functional foods formulations having clinical study reports associated with type 2 diabetes mellitus were presented in this chapter. The molecular mechanisms involved along with the primary and secondary outcomes with phytotherapy on type 2 diabetes patients were also presented. Multiple clinical studies demonstrated very prospective and potential antidiabetic activities of Berberine, Bitter gourd, Cinnamon, Curcumin, Dia-BestTM, Fenugreek, Gegen Qinlian decoction, GlucoSupreme herbal,Gymnema sylvestre, Magnesium, Nigella sativa, Resveratrol,
Tibetan medicine herb combination, TCM multiple herbal combination, Xiaoke pill, and vitamin C. Hence, at least, these phytoremedies are recommended for the management of type 2 diabetes mellitus which may have additional benefits in diabetes management compared to conventional Allopathic medicines considering the long-term safety and effectivity of the products. The updated clinical study reports on phytotherapy presented in this chapter will be helpful for the medical, biological and pharmaceutical researchers and complementary and alternative medicine users to use these plants extracts, its fractions, isolated biomolecules, herbal preparations, functional foods, nutraceuticals and other forms of phytomedicines for the prevention and treatment of diseases as well as for the discovery of modern medicines.
INTRODUCTION
Diabetes mellitus is a group of metabolic disorders characterized by high blood glucose levels. Diabetes mellitus is caused by insufficient or absence of insulin production or impairment of insulin action or both, which results with the disturbances of the metabolism of carbohydrate, protein, and fat [1]. Diabetes is classified into the following categories:
Type 1 diabetes mellitus (also called insulin-dependent diabetes): This occurs due to the destruction of pancreatic β-cells by autoimmunity, which leads to the complete deficiency of insulin production.Type 2 diabetes mellitus (also known as non-insulin dependent diabetes): This occurs because of the progressive loss of insulin production or secretion from pancreatic β-cells or the development of resistance to insulin or because of both reasons.Gestational diabetes mellitus (GDM): GDM occurs because of the hormonal and metabolic changes of pregnant women, and is diagnosed in the second or third trimester of pregnancy.Specific types of diabetes: Diabetes may also be developed due to other specific reasons, such as i) monogenic diabetes syndromes: neonatal diabetes and maturity-onset diabetes of the young, ii) diseases of the exocrine pancreas: cystic fibrosis and pancreatitis, iii) drug- or chemical-induced diabetes: glucocorticoid use in the treatment of HIV/AIDS or after organ transplantation [1, 2].Diabetes can be diagnosed by measuring fasting plasma glucose (FPG) or post-prandial plasma glucose two hours after meal (2-h PG) level or glycated hemoglobin A1C (HbA1c) criteria [2]. People with FPG ≥ 7.0 mmol/L, 2-h PG ≥ 11.1 mmol/L, HbA1c ≥ 6.5%, or random blood glucose ≥ 11.1 mmol/L in the presence of signs and symptoms are diagnosed to have diabetes [1, 3].
The prevalence and incidence of diabetes is increasing all over the world irrespective of lower-income, middle-income and developed countries. According to WHO 2018 report, the number of diabetic patients has increased from 108 million in 1980 to 422 million in 2014 [4].The global prevalence of diabetes in adults over 18 years of age has increased from 4.7% in 1980 to 8.5% in 2014 [4]. According to the report of the International Diabetic Association in 2017, approximately 425 million adults (20-79 years) were reported to live with diabetes, which is estimated to be raised to 629 million by 2045 [5]. It was found that the highest number of diabetes patients was between the age of 40-59 years, and 50% (212 million) of the people with diabetes were undiagnosed [5]. In the year 2017, more than 1.1065 million children were found to live with type 1 diabetes mellitus, and 352 million people were at risk of developing type 2 diabetes mellitus around the globe [5]. It is also noteworthy to mention here that IDF reported 79% of adults with diabetes were living in low- and middle-income countries [5].
According to WHO report 2018, an estimated 1.6 million deaths were directly caused by diabetes in 2016 and diabetes was found to be the seventh leading cause of death [4]. Diabetes is a major cause of cardiovascular diseases such as, heart attacks and stroke, kidney failure, blindness [4]. Chronic diabetes state causes severe consequences with heart attacks, stroke, blindness (due to damage to the small blood vessels in the retina), damage nerves, causes the risk of obesity, erectile dysfunction, foot ulcers, infections, kidney failure, cancer and ultimately death of the patients [1, 4, 6, 7].
The current treatment options for diabetes mellitus are oral hypoglycemic drugs and injectables, mainly insulin. Oral antihyperglycemic drugs are classified as follows:
Biguanides (Example: metformin): American Diabetic Association recommends metformin as the first line oral drug for the treatment of type 2 diabetes mellitus. Metformin reduces hepatic gluconeogenesis and lipogenesis, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization [8-10].Sulfonylureas (Examples: Glimepiride, glipizide, gliclazide): Sulfonylureas are known as insulin secretagogues because of this class of antidiabetic drugs induces the secretion of insulin from pancreatic beta-cells. American Sulfonylureas are recommended as a classic second-line therapy for the treatment of type 2 diabetes mellitus. Sulfonylureas increases insulin secretion regulated by ATP-sensitive potassium channels located in the membrane of beta cells of the pancreas [9, 11].Meglitinides (Examples: Repaglinide, nateglinide): Meglitinides are another type of oral insulin secretagogues. Meglitinides increase insulin secretion by a mechanism similar to that of sulfonylureas, but with more rapid absorption and more rapid stimulus to insulin secretion, with a shorter half-life. The insulin secretion is regulated by ATP-sensitive potassium channels located in the membrane of beta cells of the pancreas but having a different subunit of the binding site at the membrane of beta cells [9, 11, 12].α-Glucosidase inhibitors (Examples: Acarbose, miglitol, voglibose): α-glucosidase inhibitors competitively inhibit membrane-bound intestinal alpha-glucoside enzymes responsible for the digestion of dietary starch in the intestine. This causes delayed carbohydrate absorption and digestion, inhibits the reabsorption of polysaccharides as well as the metabolism of sucrose to glucose and fructose and results in a reduction in postprandial hyperglycaemia [9, 11].Thiazolidinediones (rosiglitazone, pioglitazone): Thiazolidinediones bind to peroxisome proliferator-activated receptor gamma (PPAR-γ), which is predominantly found in the central nervous system, adipose tissue and pancreatic beta-cells, to increase the sensitivity of insulin. This class of drugs thus increases peripheral uptake of glucose and decrease hepatic glucose production [9, 11].Dipeptidyl peptidase - 4 (DPP-4) inhibitors (sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin): The incretin hormones - glucagon like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), secreted by intestinal L cells, increase insulin secretion, inhibits the secretion of glucagon, decrease gastric emptying, and nourish the health of beta-cells of the pancreas. DPP-4 rapidly inactivates those incretin hormones. DPP-4 inhibitors inhibit DPP-4 enzymes, and thus facilitate to perform the activity of those two incretin hormones for a long time. By doing so, the DPP-4 inhibitors reduce glucose levels in plasma and improve islet function and health in type 2 diabetes mellitus patients [9, 11].Sodium glucose co-transporter2 (SGLT2) inhibitors (dapagliflozin and canagliflozin): SGLT2 inhibitors block sodium-glucose cotransporter 2 in proximal tubules of renal glomeruli which causes inhibition of 90% glucose reabsorption. This results an increase in glycosuria and diuresis in people with type 2 diabetes mellitus, which in turn reduces the plasma glucose levels, weight, and blood pressure [9, 11].The long-term management of type 2 diabetes mellitus (T2DM) with conventional oral hypoglycaemic drugs is a challenge as these drugs may worsen certain underlying comorbidities and complications, such as chronic kidney and cardiovascular diseases. Besides, because of the development of resistance to those drugs, it is difficult to control hyperglycemia for long term treatment of diabetes patients. This drawback of conventional medicines necessitates phytotherapy, herbal medicines, functional foods, nutraceuticals and other forms of alternative medicines or the invention of new drug molecules for the effective and long term treatment of T2DM avoiding the major adverse-effects and minimising the minor side-effects. Many experimental evidences proved the pharmacological and therapeutic potentiality and scientific basis of medicinal plants, phytocompounds, herbal preparations, functional foods and other forms of phytomedicines for use in the prevention and treatment of different diseases including diabetes [13-16], cancer [17, 18], immunity [19-23], obesity and hyperlipidemia [15, 24], oxidation, inflammation [25] and infections [26]. Plant-derived bioactive compounds are a great resource for the discovery of new medicines. Besides, the phytomedicines in the forms of extracts, isolated compounds or other forms can be used for the prevention and treatment of T2DM. This chapter contains the updated evidences from clinical study reports on different forms of phytotherapy, including plant extracts, its fractions, isolated bioactive compounds, functional foods, nutraceuticals, herbal medicines formulations and other forms of plant-derived phytoremedies reported to be beneficial in the treatment of T2DM. The functional mechanism of different forms of phytomedicines exhibited in clinical studies on type 2 diabetes patients is presented in Fig. (1).
Fig. (1)) Functional mechanism of phytotherapy in clinical studies on Type 2 diabetes mellitus patients.The updated clinical study reports on phytotherapy presented in this chapter will be helpful for the medical, biological and pharmaceutical researchers and complementary and alternative medicine practitioners and users to consider the use the potential plants extracts, its fractions, isolated biomolecules, herbal preparations, functional foods, nutraceuticals and other forms of phytomedicines for the prevention and treatment of diseases as well as for the discovery of modern medicines.
Methodology to Search Articles
In order to collect relevant information on clinical trials or clinical study reports on Phytotherapy, articles were searched systematically using the PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) search engine for accessing the MEDLINE database, Science Direct, Wiley Online Library, Clinicaltrials.org, Google scholar and Google using the following terms: “Phytotherapy for diabetes research” and “Clinical trials of phytotherapy for diabetes”. All the relevant articles, published in the English language between 1970 and August 2019, were collected for extensive review to write this book chapter.
Clinical Study Reports of Phytoremedies in Diabetes Mellitus Patients
The clinical study reports of different phytomedicines for the treatment of diabetes mellitus have been presented in Table 1 in addition to the details study report of each phytomedicine described below:
Aloe vera
Aloe vera, belongs to the Liliaceae family, is a traditional remedy for diabetes in the Arabian Peninsula [27]. Aloe gel is made from the inner portion of the Aloe vera leaf. The leaf contains glucomannan fiber, which may have prospective hypoglycemic effects [28]. In 1996, the same researcher group reported improved fasting blood glucose levels by conducting two nonrandomized clinical trials (n=76 and n=40) administering aloe gel for 6 weeks [29, 30]. Another trial using half a teaspoonful aloe gel daily was conducted among five type 2 diabetic patients for 4-14 weeks and showed a reduction in fasting blood glucose and HbA1c level [31]. A randomized, double-blind, placebo-controlled clinical trial asserted a significant decrease in fasting blood glucose, HbA1c, total cholesterol, and LDL levels two months after administering two 300 mg capsules aloe gel along with two 5 mg glyburide tablets and two 500 mg metformin tablets daily. This trial was conducted to assess the potency of these drug combinations among 30 type 2 diabetic patients aged from 40 to 60 years who were hyperlipidemic and did not take anti-hyperlipidemic agents [32].
Alpha-lipoic Acid
α-lipoic acid is a naturally occurring fatty acid and also a potent antioxidant. A multiple-dosage controlled trial was reported to have significant glucose uptake and insulin sensitivity without changing fasting blood glucose level. This trial randomly selected seventy-four patients with type 2 diabetes and among them, 19 were administered placebo whereas the rest were divided into three test groups with active treatment of α-lipoic acid in various doses daily, i.e, 600 mg once (n=19), twice (n=18), or thrice (n=18) for 4 weeks [33]. Konrad et al. performed a noncontrolled trial and compared serum lactate and pyruvate levels of diabetic patients with those of lean (n=10) and obese (n=10) healthy subjects after glucose loading. This trial showed the efficacy of α-lipoic acid in impeding hyperglycemia-induced rise of serum lactate and pyruvate levels [34].
Artocarpus heterophyllus and Asteracanthus longifolia
In 1991, Fernando MR et al. carried out a short-term non-randomized, open-label study on 20 maturity-onset diabetic patients and 20 healthy human subjects to assess the efficacy of hot-water extracts of Artocarpus heterophyllus leaves and Asteracanthus longifolia whole plant material. Both the extracts showed positive effects on glucose tolerance in the healthy subjects and the diabetic patients when 200 mL decoction, prepared from 200g fresh leaves, was administered as a single dose prior to performing GTT [35].
Bellpepper (Capsicum annuum var. Grossum) Juice
Nagasukeerthi et al. conducted a randomized controlled study on fifty T2DM patients who were divided into either study group (receiving 100 mL of bell pepper juice (twice/day) combined with an integrated approach of yoga therapy (IAYT)) or control group (receiving only IAYT) for 4-consecutive days. The study reported a significant reduction in post prandial blood glucose, systolic blood pressure, pulse pressure, rate pressure product and double product in the study group compared with control group [36].
Berberine from Berberis aristata
Several plants, for example, Berberis genus and Coptis chinensis yielded an isoquinoline alkaloid, which is called Berberine. Yin et al. carried out two trials to evaluate the efficacy of berberine (500 mg, three times a day) isolated from Berberis aristata on T2DM patients for three months. The first trial was conducted on newly diagnosed T2DM patients administering berberine or metformin. The trial exhibited a similar outcome of berberine and metformin monotherapy in reducing HbA1c, FPG, postprandial glucose, basal insulin and postprandial insulin. The second trial reported significant improvement in different parameters, like-HbA1c, FPG, PBG, basal insulin, homeostasis model assessment of insulin resistance (HOMA-IR), fasting C-peptide and postprandial C-peptide after administering berberine as adjuvant therapy in poorly controlled T2DM patients [37]. Zhang et al. also conducted a randomized, double-blind, placebo-controlled trial for 3 months using berberine (1000 mg daily). A significant decrease in HbA1c, FPG and PBG was observed among berberine group compared with the placebo group. Moreover, HbA1c reduction in test group was comparable to that of the present oral hypoglycemic drugs [38]. In 2010, another trial displayed improved insulin sensitivity using 1000 mg of berberine daily, which indicated berberine as a potent antidiabetic agent compared with metformin or rosiglitazone. This trial also showed the effectiveness of this alkaloid in maintaining a glycemic profile in patients suffering from hepatitis, whereas some current antidiabetic agents, like metformin and rosiglitazone have shown hepatic side effects [39]. Another study performed by Gu et al. (2010), also verified the effects of berberine as antihyperglycemic and antihyperlipidemic agent administering 1000 mg/day of berberine for three-months [40]. A trial was carried out in patients with 5.6-7.5 baseline HbA1c level co-morbid with non-alcoholic fatty liver disease using treatments include life style intervention (LSI) alone or combined with berberine or pioglitazone for 4 months. Significant reduction was found in HbA1c along with other glycemic parameters in combination therapy rather than LSI only, which were similar to that of pioglitazone [41]. However, the potential effects of berberine (900 mg/d) on glycemic, lipidemic, and anthropometric parameters as well as the inflammatory parameters including CPR, LPS, and TNF-α were ascertained after a two month trial on T2DM patients [42]. In 2018, Lazavi F et al. performed a randomized clinical trial feeding with 200 ml barberry juice (BJ) daily for eight weeks. Total Cholesterol and triglyceride level were significantly reduced in BJ group [43].
Berberol
Berberol is a nutraceutical mixture made from Berberis aristata extract (588 mg, standardized based on 85% berberine), and Silybum marianum extract (105 mg, standardized based on 60% flavonolignans) [44]. In 2012, Di Pierro et al. performed a clinical trial on T2DM patients with trivial glycemic control using berberol two times a day for three months. HbA1c, basal insulin and HOMA-IR were significantly decreased. The outcomes of this trial indicated that berberol could be a potential supplement to increase insulin sensitivity [45]. Di Pierro et al. (2013) conducted another trial administering berberine (1000 mg/d) or berberol (two times a day) in two separate groups of T2DM patients for 4 months. Both formulations significantly reduced HbA1c and FPG; however, berberol was more potent in reducing HbA1c level than berberine. SGOT and SGPT were also reduced, which is similar to the previous trial [46]. In 2015, another study was carried out to assess the effectiveness of berberol in 45 hypercholesterolemic T2DM patients with statin intolerance for 12 months. All the patients were divided into three groups: control group (n=15) who were not taking hypolipidemic drugs due to a recent diagnosis of hypercholesterolemia and statin intolerance; 15 were diagnosed with hypercholesterolemia and treated with ezetimibe (10 mg/day) due to statin intolerance diagnosed in the previous year; 15 were being treated with low doses of statins due to a diagnosed intolerance to high-dosage statins. Significant improvement in HbA1c and FPG, as well as lipid profile, were found in all groups of patients without any serious side effects [47].
Bitter Gourd (Momordica charantia)
Active components of Momordica charantia (balsam pear/karolla/bitter gourd/bitter melon) are charantin, vicine, and polypeptide-p (unidentified insulin-like protein resembles bovine insulin) [48]. Welihinda et al. reported strong beneficial effects of M. charantia fruit juice (100 ml, 30 min before the oral glucose load) on blood glucose by performing a short-term controlled metabolic trial on 18 type 2 diabetic patients [49]. In another trial, nine patients were administered with subcutaneous vegetable insulin extract (purified protein extract of fruits and tissue cultures of M. charantia), which was shown to have a consistent hypoglycaemic effect with no hypersensitivity reaction to this extract. The onset of action of this plant insulin was within 30-60 min with the peak effect six hours after the administration [50]. A 4-week, multicenter, randomized, double-blind, active-control trial was carried out among 120 patients with type 2 diabetes. The patients were divided into 4 groups administering bitter melon 500 mg/day, 1000 mg/day, and 2000 mg/day or metformin 1000 mg/day. The findings of the trial indicated that the dosage 2000 mg/day of bitter melon possessed modest hypoglycemic effect as well as significantly decreased fructosamine levels [51]. Another systematic review has been performed using bitter gourd preparations by Peter et al., which also confirmed that these preparations have beneficial effects in lowering elevated fasting plasma glucose in prediabetes [52].
Carnitine
Carnitine or its derivative acetyl-L-carnitine was given to type 2 diabetic patients to evaluate its efficacy in improving blood glucose levels. Three small controlled short-term metabolic trials were found that revealed the positive effects of intravenous carnitine administration (n=18, n=15, and n=9) in enhancing insulin sensitivity as well as glucose uptake and storage [53-55].
Caucasian Whortleberry (Vaccinium arctostaphylos L.)
Mirfeizi et al. performed a randomized triple-blinded clinical trial on 105 T2DM patients using 1000 mg/day cinnamon (n=30), 1000 mg/day Caucasian whortleberry (n=30) and 1000 mg/day starch (placebo group, n=45) for 3 months. Both cinnamon and whortleberry significantly reduced FBG, 2-h PPG, insulin serum, HbA1c, and HOMA-IR levels in diabetic patients compared to the placebo group [56].
Celery (Apium graveolens L.)
In a randomized clinical trial, Yusni et al. (2018) found promising improvement in pre-prandial and post-prandial plasma glucose levels after treating 16 elderly pre-diabetic patients with celery leaf (capsules obtained from A. graveolens leaf extract at the dose of 250 mg, 3 times per day) for 12 days [57].
Chromium
Chromium (Cr3) has potent hypoglycemic activity and its trivalent form is required to maintain glucose metabolism. A double-blind, placebo-controlled, crossover study was performed on 30 T2DM patients receiving either chromium picolinate or placebo for 2 months. This trial showed a significant decrease in triglyceride levels without any significant difference between the control and chromium-treated subjects in glucose control, high-density lipoprotein cholesterol levels, or low-density lipoprotein cholesterol levels [58]. In a double-blind, randomized clinical trial, chromium picolinate treated group showed a significant reduction in fasting and 2-h insulin levels after 2 and 4 months supplementation. The trial enrolled 180 type 2 diabetic patients and divided them into three groups administering either placebo, or 1.92 μmol (100 μg) Cr as chromium picolinate two times per day, or 9.6 μmol (500 μg) Cr two times per day [59]. 29 obese subjects who have family history of Type 2 diabetes were allocated randomly in two groups in a double-blind, randomized, placebo-controlled trial for 8 months. The subjects were treated with either 1,000 μg/day chromium picolinate (CrPic) or placebo. Chromium picolinate displayed significant improvement in insulin sensitivity [60]. Another double-blind, randomized, cross-over study enrolled seventy eight type 2 diabetic patients administering either Brewer’s yeast (23.3 ug Cr/day), or CrCl3 (200 ug Cr/day) sequentially with placebo in between, comprised of four stages, each lasting 8 weeks. Different blood glucose parameters like- fasting and 2 hour post glucose level, fructosamine as well as triglycerides levels were found to decrease significantly after supplementation with both the doses [61]. Another trial was conducted to evaluate the efficacy of yeast containing a high amount of chromium (160µg/d in 4 pellets) supplementation in elderly subjects (n=26) with stable impaired glucose tolerance. However, there was no improvement in glucose tolerance or serum lipid levels [62]. Anderson et al. (1991) showed that supplemental chromium (chromium chloride; 200µg/d) caused significant improvements in glucose, insulin, and glucagon variables in subjects with marginally elevated blood glucose [63]. In 1992, Abraham et al. performed a trial on 25 patients with stable non-insulin-dependent diabetes mellitus administering daily with either 250 μg of chromium orally (chromium chloride) or a placebo for a period of 7 to 16 months. They revealed that there was no considerable change in fasting blood glucose level in diabetic or nondiabetic subjects after chromium supplementation for periods of up to 16 months [64]. However, Anderson et al. (2001) suggested the potential antioxidant effects of the individual and combined supplementation of Zn and Cr in 110 type 2 DM patients [65].
Cinnamon (Cinnamomum zeylanicum)
Cinnamon has been extensively studied for its therapeutic efficacy and safety in clinical trials. A meta-analysis of 10 randomized controlled trials which included 543 patients with type 2 diabetes mellitus and used cinnamon (Cinnamomum zeylanicum) doses starting from 120 mg to 6 g per day in different clinical studies for a period of four to eighteen weeks resulted with the reduction of fasting plasma glucose (-24.59 mg/dL), total cholesterol (–15.60 mg/dL), LDL-C (–9.42 mg/dL) and triglycerides (–29.59 mg/dL) levels, and increased the levels of HDL-C (1.66 mg/dL) in diabetes patients. But cinnamon could not significantly reduce the HbA1c levels (–0.16%) in diabetes patients [66]. In a 4 months double-blind randomized trial, 79 type 2 diabetes mellitus patients, taking oral antidiabetics or diet, were allocated to take either the cinnamon extract (3 g of cinnamon powder) or a placebo capsule (three times) daily. The findings of this trial showed that cinnamon extract significantly decreased the blood glucose level in cinnamon group (10·3%) comparing to placebo group (3·4%) without any adverse-effect [67].
Coccinia indica
The coccinia powder is obtained from crushed freeze-dried leaves of Coccinia indica. The powder was reported to have significant effects in improving blood glucose level among poorly controlled or untreated type 2 diabetic patients (n=32) after 6 weeks of administration, in a double-blind control trial, conducted in 1979 [68]. In another controlled clinical trial, pellets made from fresh dried leaves were used to compare its efficacy with a conventional hypoglycemic drug (chlopropamide) on 70 type 2 diabetic patients for 12 weeks. The findings showed that the herb ameliorated different blood glucose parameters similar to that of the drug [69]. Kamble SM et al. revealed that C. indica acts like insulin in an open-label trial following six weeks’ use of dried extract of the herb orally in 30 diabetic patients at a dose of 500 mg/kg body weight [70].
Corn Bran (Zea Species)
Hanai et al
